FDA Approves Qfitlia to Cut Bleeding Episodes in Patients With Hemophilia
The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the ...
Managed Healthcare Executive1d
Costs of Hemophilia With Inhibitors Are High, Warranting Better Management | AMCP Annual 2025
The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...
BioSpace6d
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
Zacks.com on MSN5d
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without ...
Sanofi: Qfitlia Approval A Bright Spot As Landscape Darkens For European Pharma
Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.
PharmExec5d
FDA Approves Sanofi’s Qfitlia for Prophylaxis in Patients with Hemophilia A or B
Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce ...
FDA Approves Sanofi's Hemophilia Drug
FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...
Clinical Advisor1d
Qfitlia, a Novel Treatment for Hemophilia A or B, Gets FDA Approval
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
Technology Networks6d
FDA Approves Novel Treatment for Hemophilia A or B
The FDA has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in ...
GEN - Genetic Engineering and Biotechnology News6d
RNAi Therapeutic for Hemophilia A or B Gets FDA Approval
Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.
Medical Dialogues5d
FDA Approves fitusiran for Hemophilia A and B
The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...
The Pharma Letter3d
NICE recommends Sobi’s Altuvoct for severe hemophilia A
Swedish Orphan Biovitrum, the Nordic biotech also known as Sobi, has announced that the National Institute for Health and ...